Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
Latest Information Update: 17 Dec 2024
Price :
$35 *
At a glance
- Drugs Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy Leman Biotech (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- 09 Dec 2024 New trial record